Reviews and reports
These publications may be of interest to anyone involved in this research agenda. Some are written for the non-expert audience and others are aimed at the scientific expert.
2016: IMI Consultation ATMP MRC MHRA and HRA Response
The MRC working with MHRA and HRA have responded to the Innovative Medicines Initiative (IMI) consultation on Advanced Therapies Concept Paper.
This concept paper is part of a project to identify how IMI can support the EU realise the benefits of advanced therapies for patients.
2015: The Hinxton Group: Statement on Genome Editing Technologies and Human Germline Genetic Modification
The Hinxton Group discussed the scientific, ethical and regulatory issues raised by the rapid advances in genome editing technologies across both basic and clinical research and potential future applications to produce a consensus statement, focussing on genome editing in the early stages of human development, when any such intervention might reasonably be assumed to integrate into the germline, and therefore have the opportunity of being passed down to future generations. MRC has similarly published its policy regarding genome editing, building on a Joint Statement with the AMRC, Academy of Medical Sciences, BBSRC and the Wellcome Trust.
2012: Ministerial Industry Strategy Group Forum on the regulation of regenerative medicine
The workshop addressed:
- The current regulatory environment in the UK and Europe, and its suitability for the current R&D needs for cell-based regenerative medicine.
- The key areas of regulatory uncertainty and concern regarding the development of cell-based regenerative therapies.
- The likely needs for future scientific progress.
2012: A Strategy for UK Regenerative Medicine
The review identifies the opportunities and challenges faced by the UK regenerative medicine community, spanning discovery and translational science and the needs for clinical delivery.
The findings have been used to develop a UK strategy and route map for future investment for regenerative medicine.
While focused on the research and development agenda where the sponsor group has greatest influence, this strategy has also considered barriers to application in areas beyond the immediate research domain.
2011: Forward Look in Regenerative Medicine
The forward look is the research community’s view on the future priorities for regenerative medicine research and development - taking into account current activities, opportunities, and scientific, clinical and commercial relevance.
The workshop was sponsored by four Research Councils (MRC, BBSRC, EPSRC and ESRC) and the Technology Strategy Board (now Innovate UK). Experts, from industry, academia, venture capitalists and regulatory authorities shared views on the key objectives for the field, the drivers shaping them, the field’s current position, perceived barriers to progress, the requirements needed to meet the identified objectives.
The forward look also drew on the findings of the Government-led report Taking Stock of Regenerative Medicine in the UK, published in July 2011.
2010 CIRM-MRC Human Somatic Cell Nuclear Transfer Workshop Report
The MRC and Californian Institute for Regenerative Medicine (CIRM) held a joint workshop in 2010 to examine the status of human somatic cell nuclear transfer and its future role in stem cell research. The workshop report summarises the 2010 state of the global research effort in this area.